Navigation Links
Accelovance Primed to Achieve Leadership in Oncology Clinical Trials

ROCKVILLE, Md., July 10, 2013 /PRNewswire-USNewswire/ -- This spring has seen Accelovance, a Rockville, Md. Clinical Research Organization (CRO) serving biotech and small and mid-sized pharmaceutical companies, advance its goal of providing premier services within oncology clinical research.  

The company successfully completed its first-ever "Oncology Protocol Challenge" at the American Society for Clinical Oncology (ASCO) last month and appointed two senior level executives who will increase the company's capabilities in organizing and conducting early stage oncology clinical trials. 

The Oncology Protocol Challenge-
Accelovance developed its Oncology Protocol Challenge as a complementary service to support the cancer research community at ASCO last month.   Responses from participating sponsors were extremely favorable at this major international medical congress.   

The Initiative encouraged clinical trial sponsor companies to "challenge" the Accelovance scientific team to review their protocols or clinical development plans and provide practical feedback encompassing operational, scientific, and therapeutic factors on a no-cost basis.    The Accelovance team thoroughly dissected the companies' studies and methodologies prior to ASCO, prepared comprehensive summaries of their viewpoints and recommendations and met with the companies at private meetings at ASCO to present their findings.  

Michael Keens, VP Sales and Marketing, at Accelovance, says, "this was an innovative and engaging means for companies to 'pressure test' their clinical trial protocols with outside, neutral experts.  Having our team review their plans helped several companies ensure that they were organizing trials in the most cost-effective, operational, and expeditious manner."

Boosting Accelovance Scientific Resources-
Accelovance made several hires in the first half of 2013 to bolster its capabilities in oncology clinical trials.

Jamie Oliver, Pharm.D., was appointed Senior Vice President, Clinical Services.   Dr. Oliver was previously Chief Executive Officer at Phage Pharmaceuticals, Inc., and prior to Phage was a Principal at Trinity Drug Partners, L.L.C.   He has published a number of peer-reviewed articles in the areas of oncology and immunopharmacology.   He received his Doctor of Pharmacology degree from Mercer University in Atlanta.

Robert C. Shepard, M.D., Ph.D., was named Vice President, Scientific and Medical Affairs, Oncology.    Dr. Shepard is an attending physician at the Duke University School of Medicine and was previously Chief Medical Officer at Cornerstone Pharmaceuticals. He is triple boarded in Oncology, Hematology and Internal medicine, authoring numerous peer-reviewed papers, primarily within oncology.   He is a graduate of the Duke University School of Medicine. 

Drs. Oliver and Shepard join Ralph Boccia, M.D., the company's Oncology Medical Director.  Dr. Boccia is also Medical Director of the Center for Cancer and Blood Disorders in Bethesda, Md.

Stephen J, Trevisan, CEO of Accelovance says "we are thrilled to add Jamie and Rob to our team.  The need for development and operational assistance in cancer clinical trials continues to grow and there is an acute demand for hands-on leaders to manage the complex issues related to trial design and clinical oversight, patient recruitment and data management. Creating programs such as the Oncology Protocol Challenge provides value to drug development companies, and Accelovance is proud to apply our heritage of successful trial management and leverage the expertise of our Senior Leaders and staff to the oncology arena." 

"Our goal is to be a leader in early phase Oncology clinical trials and these appointments—along with the continued involvement of Dr. Ralph Boccia— underscore our commitment to this goal."

About Accelovance
Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. The Company was recognized as "Best CRO" with consecutive Industry Excellence awards in 2009, 2010 and 2011. Accelovance tailors its full offering of CRO services to present a clinical solution that meets a sponsor's needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.

For more information, visit the company's website at

Press Contact:  Michael Keens

SOURCE Accelovance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelovance Expands Oncology Leadership with the Addition of Ralph Boccia, MD as Oncology Medical Director
2. Accelovance Expansion Continues with Acquisition of Radiant Development, the CRO Division of Radiant Research
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Seventeen Banner Health facilities achieve final stage of electronic medical record adoption
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Greenville Hospital System Achieves Dramatic Improvement in Hand Hygiene Compliance Rates Using New Technology from DebMed®
7. Fluke Biomedical device first to achieve environmentally-friendly label
8. Acuo Technologies Grows European Business and Achieves Successful Connectathon Results in Bern, Switzerland
9. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Honored Dr. Thomas Fogarty with the 2012 Lifetime Achievement Award
10. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
11. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
Post Your Comments:
(Date:11/24/2015)... Connecticut , November 24, 2015 ... of Acadiana has entered into a multi-year agreement ... imaging centers. This investment will provide the Breast Center ... --> Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
(Date:11/24/2015)... -- iRhythm Technologies, Inc. , a leading digital health care ... will participate in the 27th Annual Piper Jaffray Healthcare Conference at ... . Kevin King , Chief Executive Officer of ... 8:50am ET. --> --> ... . --> iRhythm is a privately held ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
(Date:11/24/2015)... ... 2015 , ... Sir Grout of Baltimore is proud to ... award recognizes good companies for excellence in service and a commitment to the ... surface restoration company earned this recognition after a thorough review by the acclaimed ...
Breaking Medicine News(10 mins):